TY - JOUR
T1 - Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas
AU - Fassan, Matteo
AU - Ludwig, Kathrin
AU - Pizzi, Marco
AU - Castoro, Carlo
AU - Guzzardo, Vincenza
AU - Balistreri, Mariangela
AU - Zaninotto, Giovanni
AU - Ruol, Alberto
AU - Giacomelli, Luciano
AU - Ancona, Ermanno
AU - Rugge, Massimo
PY - 2012/8
Y1 - 2012/8
N2 - Differences in human epithelial growth factor receptor 2 dysregulation in primary solid tumors and metastases may (at least partially) explain human epithelial growth factor receptor 2-targeted therapeutic inconsistencies. Human epithelial growth factor receptor 2 status was tested in a series of 47 radically treated consecutive esophagogastric junction adenocarcinomas (male/female, 38/9; mean age, 67.9 years) in both primary cancers and paired synchronous nodal metastases. None of the patients received neoadjuvant therapy. For each case, 2 nonadjacent tissue samples from primary esophagogastric junction adenocarcinoma and 2 different metastatic nodes were considered (188 tissue samples in all). Human epithelial growth factor receptor 2 status was assessed by immunohistochemistry (PATHWAY-HER2/neu [4B5]; Ventana Medical Systems, Milan, Italy) and dual chromogenic in situ hybridization (duoCISH; DAKO, Glostrup, Denmark). Immunohistochemistry staining scores were nil in 22 tumors (47%), 1 (21%) in 10, 2 (13%) in 6, and 3 (19%) in 9. Human epithelial growth factor receptor 2 gene amplification (25.5%) was associated with more differentiated phenotype (Fisher exact test, P =.039) and advanced tumor stage (Fisher exact test, P =.015). Significant agreement was observed between human epithelial growth factor receptor 2 protein expression (immunohistochemistry) and human epithelial growth factor receptor 2 gene's amplification (chromogenic in situ hybridization) (κ = 0.84, P
AB - Differences in human epithelial growth factor receptor 2 dysregulation in primary solid tumors and metastases may (at least partially) explain human epithelial growth factor receptor 2-targeted therapeutic inconsistencies. Human epithelial growth factor receptor 2 status was tested in a series of 47 radically treated consecutive esophagogastric junction adenocarcinomas (male/female, 38/9; mean age, 67.9 years) in both primary cancers and paired synchronous nodal metastases. None of the patients received neoadjuvant therapy. For each case, 2 nonadjacent tissue samples from primary esophagogastric junction adenocarcinoma and 2 different metastatic nodes were considered (188 tissue samples in all). Human epithelial growth factor receptor 2 status was assessed by immunohistochemistry (PATHWAY-HER2/neu [4B5]; Ventana Medical Systems, Milan, Italy) and dual chromogenic in situ hybridization (duoCISH; DAKO, Glostrup, Denmark). Immunohistochemistry staining scores were nil in 22 tumors (47%), 1 (21%) in 10, 2 (13%) in 6, and 3 (19%) in 9. Human epithelial growth factor receptor 2 gene amplification (25.5%) was associated with more differentiated phenotype (Fisher exact test, P =.039) and advanced tumor stage (Fisher exact test, P =.015). Significant agreement was observed between human epithelial growth factor receptor 2 protein expression (immunohistochemistry) and human epithelial growth factor receptor 2 gene's amplification (chromogenic in situ hybridization) (κ = 0.84, P
KW - Adenocarcinoma
KW - HER2
KW - Immunohistochemistry
KW - ISH
UR - http://www.scopus.com/inward/record.url?scp=84863985197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863985197&partnerID=8YFLogxK
U2 - 10.1016/j.humpath.2011.09.004
DO - 10.1016/j.humpath.2011.09.004
M3 - Article
C2 - 22217477
AN - SCOPUS:84863985197
VL - 43
SP - 1206
EP - 1212
JO - Human Pathology
JF - Human Pathology
SN - 0046-8177
IS - 8
ER -